Duck plague virus (DPV) is a virus of the Herpesviridae family that leads to acute disease with a high mortality rate in ducks. Control of the disease contributes to the development of poultry breeding. Type III IFN family (IFN-ls) is a novel member of the IFN family, and goose IFN-l (goIFN-l) is a newly identified gene whose antiviral function has only been investigated to a limited extent. Here, the cross-species antiviral activity of goIFN-l against DPV in duck embryo fibroblasts (DEFs) was studied. We found that pre-treatment with goIFN-l greatly increased the expression of IFN-l in both heterologous DEFs and homologous goose embryo fibroblasts (GEFs), while differentially inducing IFNa-and IFN-stimulated genes. Additionally, a positive self-regulatory feedback loop of goIFN-l was blocked by a mouse anti-goIFN-l polyclonal antibody, which was confirmed in both homologous GEFs and goose peripheral blood mononuclear cells (PBMCs). The suppression of the BAC-DPV-EGFP by goIFN-l in DEFs was confirmed by fluorescence microscopy, flow cytometry (FCM) analysis, viral copies and titre detection, which can be rescued by mouse anti-goIFN-l polyclonal antibody incubation. Finally, reporter gene assays indicated that the cross-species antiviral activity of goIFN-l against BAC-DPV-EGFP is related to its positive self-regulatory feedback loop and subsequent ISG induction. Our data shed light on the fundamental mechanisms of goIFN-l antiviral function in vitro and extend the considerable range of therapeutic applications in multiple-poultry disease
INTRODUCTION
Interferons (IFNs) are essential components of host innate and adaptive immune responses that serve as the first line of defence against invading viruses and are exploited as an effective treatment for several cancers and autoimmune diseases [1] . Three types of IFNs (types I, II and III) have been discovered in mammals, and their function is associated with the structure and biological characteristics of their receptors [2] . The type I IFN family is composed of IFN-a, IFN-b and others (IFN-", IFN-k, IFN-d and IFN-!) [3] [4] [5] [6] . IFN-g is the sole type II IFN. In addition, a novel IFN family (type III IFN) was first identified in 2003 and includes IFN-l1 (IL-29), IFN-l2 (IL-28A), IFN-l3 (IL-28B) and IFN-l4 [7] . IFN-l is expressed in a limited number of cells and tissues due to the responses associated with IFN-l receptor expression [8] . Interestingly, the type III interferon (IFN-l) family shares common signalling pathways with type I IFNs. IFN-l binds to two chains of transmembrane receptor proteins (IFNLR1A and IL10RB) and acts through the same Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway to stimulate the formation of an IFN-stimulated gene factor 3 (ISGF3) trimer [6, 9] . Subsequently, ISGF3 translocates into the nucleus and binds to IFN-stimulated response elements (ISRE), inducing interferon-stimulated genes (ISGs) [6, 9] . Accumulating data have suggested that type III IFN plays an essential role in the response to viral or bacterial invasion by inducing the expression of downstream ISGs such as Mx1, OAS or IFIT [5, 10, 11] . Notably, recent in vitro studies have reported that IFN-l contributes to the control of chronic viral infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV) [4] . However, the mechanisms underlying IFN-l activity against chronic viral infections require further investigation.
In poultry, type III IFN has only been identified in ducks and chicken, with a limited investigation on antiviral function [12, 13] . Chicken IFN-l (chIFN-l) has weak inhibitory effects on vesicular stomatitis virus (VSV) and influenza virus (WSN strain, H1N1) in the DF-1 fibroblast cell line, but markedly inhibited the replication of these viral strains in ovo and in vivo, as well as in epithelium-rich tissue and cell-culture systems [14] . These results demonstrated that the antiviral function of IFN-l depended on the expression of its cognate receptor in certain cells. Additional evidence indicates that chIFN-l has a strong inhibitory effect on Semliki Forest virus (SFV) infection in chicken embryo fibroblasts (CEFs) and inhibits the replication of influenza virus (H1N1) in HD11 cells [12] . The overexpression of duIFN-l in primary duck hepatocytes (PDHs) significantly up-regulated duOASL and duMx, and the role of duIFN-l in the response to avian influenza virus and duck hepatitis B virus infection has been reported [13] . The expression of both duIFN-l and chIFN-l was up-regulated following influenza virus (H1N1) infection [15] . Aquatic birds, especially of the orders Anseriformes (ducks and geese) and Charadriiformes (shorebirds), are considered to be the biological and genetic reservoirs of many important pathogens, such as AI viruses.
However, at this time, there are virtually no reports on goose IFN-l (goIFN-l). Recently, we cloned goIFN-l and identified its tissue expression profile [16] . Here, several experiments were performed to investigate the ability of goIFN-l to inhibit duck plague virus (DPV) replication in duck embryo fibroblasts (DEFs). To address this issue, the expression of three types of IFNs (IFNa, IFNg and IFNl) and ISGs (Mx and OASL) was measured in DEFs and goose peripheral blood mononuclear cells (goPBMCs) after goIFN-l or mouse antigoIFN-l polyclonal antibody (anti-goIFN-l PAb) pretreatment. Moreover, reporter gene assays were employed to confirm that the cross-species antiviral activity of goIFN-l against BAC-DPV-EGFP is related to its positive self-regulatory feedback loop and subsequent ISGs induction. Collectively, these results are of fundamental use in extending our understanding of goIFN-l antiviral function mechanisms and might be capable of producing broad-spectrum antiviral medicine for animal viral disease.
RESULTS
Prokaryotic expression of recombinant goIFN-l and reactivity of polyclonal antibody Recombinant goIFN-l was expressed from the pET-32a (+)-goIFN-l plasmid in BL21 cells, and the resulting product was analysed by SDS-PAGE. The pET-32a (+)-goIFN-l fusion protein was expressed with an estimated molecular weight of 41 kDa. No protein was isolated from pET32a (+) (Fig. 1a, lane 1) or pET32a (+)-goIFN-l (Fig. 1a, lane 3) -transformed E. coli cells without IPTG induction. In contrast, we observed the expected protein in pET32a (+) (Fig. 1a, lane 2) and pET32a (+)-goIFN-l (Fig. 1a, lane 4) -transformed E. coli cells after induction with IPTG (at a final concentration of 0.8 mM). In addition, the fusion protein (pET-32a (+)-goIFN-l) was purified by Ni-NTA affinity chromatography using His-bind Resin. A clear band corresponding to the expected molecular weight (approximately 41 kDa) can be observed in Fig. 1(a) , lane 5.
The purified fusion protein was used as an immunogen to prepare anti-goIFN-l PAb. The anti-goIFN-l PAb titre was greater than 1 : 6,400, as determined by indirect ELISA (data not shown) and confirmed by Western blot (Fig. 1b) . The Western blot analysis demonstrated that goIFN-l was expressed in the supernatant of pcDNA 3.1(+)-goIFN-ltransfected cells at 72 h and was recognized by a mouse histagged monoclonal antibody (Sangon Biotech, Shanghai, China) as well as the anti-goIFN-l PAb (Fig. 1b) .
Eukaryotic expression of goIFN-l
The goIFN-l open reading frame (ORF) was amplified and successfully subcloned into the pcDNA3.1 (+) expression vector (pcDNA3.1 (+)-goIFN-l). The pcDNA 3.1(+)-goIFN-l plasmid or empty vector was transfected into BHK-21 cells. Cell lysates and culture supernatants were harvested 24, 48 or 72 h after transfection for subsequent Western blot analysis. goIFN-l was expressed at 24, 48 and 72 h post-transfection in both cell lysates (Fig. S1a , available in the online Supplementary Material) and culture supernatants (Fig. S1b) . In addition, Western blot analysis showed that the molecular size of goIFN-l (with the 1 kDa his tag) was approximately 21 kDa (Fig. 1c) . Of these treatments, the culture supernatant obtained 24 h post-transfection was chosen for further study of goIFN-l. Briefly, goIFN-l can be successfully overexpressed in pcDNA3.1 (+)-goIFN-ltransfected BHK-21 cells.
Immunoregulation study of goIFN-l in DEF cells
In our previous study, the goIFN-lR1 showed high amino acid identity (90 %) with duIFN-lR1 [17] , although goIFN-l shared a comparatively lower identity to duIFNl (65.1 %) (Fig. 2) . However, we found that residues R 55 huIFN-l , L 56 huIFN-l , Q 100 huIFN-l and F 158 huIFN-l were conserved in both goose and duck, and this had a critical role in receptor binding and antiviral activity of huIFN-l (Fig. 2 ) [18] . Therefore, we hypothesized that goIFN-l might be recognized by duIFN-lR1 and display a cross-species antiviral activity.
To further confirm our hypothesis, we attempted to obtain an insight into the immunoregulatory effects of goIFN-l on DEFs, GEFs and goPBMCs and determined the expression of IFN (IFN-a, IFN-g and IFN-l) and ISG (Mx and OASL) mRNAs by qPCR. The CCK-8 assay for cytotoxicity showed that cell viability was not overtly affected in DEFs treated with goIFN-l for 3, 6, 12 and 24 h, demonstrating that goIFN-l does not have detrimental effects on DEFs (Fig.  S2 ). DEFs were stimulated with goIFN-l for 6, 12 and 24 h. Not surprisingly, the expression of duIFN-l mRNA was significantly up-regulated at every time point (P<0.05, P<0.01 and P<0.05 for 6, 12 and 24 h, respectively), and the expression of duIFN-a mRNA was significantly up-regulated at 6 and 12 h (P<0.05 for 6 h; P<0.01 for 12 h) (Fig. 3a) . goIFN-l only increased duIFN-g expression at 6 h (P<0.05) and duOASL expression at 12 h (P<0.05) (Fig. 3a) . Interestingly, there was a slight change in duMx expression at all time points (Fig. 3a) . Goose PBMCs were also treated with goIFN-l. The results indicated that goIFN-l had stronger effects on PBMCs than DEFs. Similarly, the expression of goIFN-l was significantly up-regulated at every time point, most likely due to a positive self-regulatory loop (P<0.001 for 6, 12 and 24 h) (Fig. 3b) . goIFN-l also up-regulated goIFN-a expression at 6 and 12 h (P<0.01 for 6 and 12 h), while goIFN-g expression was significantly up-regulated in response to goIFN-l treatment. In addition, goMx expression was significantly up-regulated at every time point (P<0.01 for 6 h; P<0.05 for 12 h; P<0.05 for 24 h), while goOASL expression was significantly up-regulated at 6 and 12 h (P<0.01 for 6 and 12 h) (Fig. 3b) .
Furthermore, to confirm the immunoregulatory effects of goIFN-l on GEFs, the level of goose Mx, OASL, IFN-a, IFN-g and IFN-l mRNAs in pcDNA3.1 (+)-goIFN-ltransfected GEFs was detected (Fig. S3) . These results showed that goIFN-l was significantly up-regulated by goIFN-l treatment at all time points (P<0.001 for 6 h and 12 h; P<0.05 for 24 h). Both goMx and goOASL expression increased significantly after goIFN-l treatment for 12 h (P<0.001 for goMx; P<0.05 for goOASL). Taken together, these data prompted the suggestion that goIFN-l can be recognized by the duIFN-l receptor, triggering the transcription of duck ISGs, although the response to goose IFN-l in DEFs was less pronounced than in GEFs and goPBMCs.
The positive self-regulatory feedback loop of goIFN-l in DEF cells is disrupted by anti-goIFN-l PAb To further confirm the goIFN-l positive self-regulatory feedback loop, an antibody-blocking assay was conducted by incubating goIFN-l-treated DEFs and goPBMCs with a mouse anti-goIFN-l PAb. Initially, the DEFs were incubated with PBS or anti-goIFN-l PAb (100 µl/well) for 3 h before goIFN-l (100 µl/well) was added into each well for another 9 h. The results (Fig. 4a) showed that the duIFN-l level was significantly reduced by anti-goIFN-l PAb pretreatment (P<0.05). Interestingly, the expression of both goMx and goIFN-a were significantly up-regulated after anti-goIFN-l PAb treatment in DEFs (P<0.05; P<0.05) (Fig. 4a) . Meanwhile, our results showed that the expression levels of both duISGs and goISGs in vitro were not affected by treatment with mouse-negative serum (isotype control) compared to empty control (Fig. S4a, b ). These data demonstrated that the anti-goIFN-l PAb was able to block the goIFN-l positive self-regulatory feedback loop in DEFs. Furthermore, the goIFN-l positive self-regulatory feedback loop was also blocked in goPBMCs (Fig. 4b) . Collectively, the data suggested that the self-induction of duIFN-l and goIFN-l was specifically reduced by anti-goIFN-l PAb treatment in vitro.
Antiviral activity of goIFN-l against DPV in DEF cells BAC-DPV-EGFP was used to assess the antiviral activity of goIFN-l in heterologous cells. Initially, cells seeded in 12-well plates were pre-treated with several doses of goIFN-l (25, 50, 75 or 100 µl per well) or anti-goIFN-l PAb (25, 50, 75 or 100 µl per well). The control group was treated with the same dose of pcDNA3.1 (+)-transfected BHK-21 cells. Then, 12 h later, all of the wells were infected with BAC-DPV-EGFP (100 µl per well, which contained 100 TCID 50 ). According to the fluorescence values, goIFN-l exerts an inhibitory effect on BAC-DPV-EGFP replication at 48 and 60 h p.i. in DEFs (the 75 and 100 µl per well dose groups) (Fig. 5a ), and the fluorescence values were higher in the anti-goIFN-l PAb-treated group than in the control group (Fig. 5a ). FCM revealed that the percentage of EGFPpositive cells was reduced by goIFN-l incubation in a dosedependent manner (75 µl, 100 µl) at 48 (5.31 %, 4.09 %) and 60 h p.i. (10.01 %, 6.78 %) (Fig. 5b) . However, at 48 and 60 h p.i., the percentage of EGFP-positive cells in the antigoIFN-l PAb-treated group was dramatically higher than that in the goIFN-l-treated and the control groups (Fig. S5b) . Furthermore, the viral copies and titres were detected by qPCR and TCID 50 , respectively. At 48 h p.i., the viral copies were significantly decreased by 75 and 100 µl goIFN-l treatment (P<0.001; P<0.001), while the viral copies were significantly decreased by 50, 75 and 100 µl goIFN-l treatment (P<0.001; P<0.001; P<0.001) (Fig. 5c) . Additionally, the viral copies were always much higher in the anti-goIFN-l PAb-treated cells than in the goIFN-ltreated and the control groups (P<0.001) (Fig. S5c) . Moreover, as the results of the TCID 50 assay show, at 48 and 60 h p.i., the viral titres were significantly lower in the goIFN-l treated group than in the control group (P<0.001 for 48 and 60 h p.i.) (Fig. 5d) , while the viral titres of the anti-goIFN-l PAb-treated group were significant higher than those of the control group at 48 and 60 h p.i. (P<0.001 for 48 and 60 h p.i.) (Fig. S5d) . Taking these results together, treatment of DEFs with goIFN-l provides a certain degree of protection against DPV infection in a dose-dependent manner, and neutralization of the effect of endogenous IFN-l contributes to enhancement of the sensitivity of DEFs to DPV.
Suppression of DPV by goIFN-l can be rescued by anti-goIFN-l PAb incubation
To further investigate whether the suppression of DPV by goIFN-l can be affected by anti-goIFN-l PAb incubation, we performed the experiments described in Fig. 6(a) . As shown in Fig. 6(b-e) , the replication of virus was significantly inhibited by goIFN-l, and the antiviral effect of goIFN-l against DPV can be successfully blocked by the anti-goIFN-l PAb. Meanwhile, there were no differences between the empty control and the isotype control for the DPV fluorescence values at 24, 48, 72 h p.i. (Fig. S6a) , and this also applied to virus copy detection (72 h p.i.) (Fig.  S6b) . Moreover, at 48 h p.i., higher luciferase activity was observed for both pGL3-IFNb-Luc and pGL4-IRSE-Luc in goIFN-l pre-stimulated DPV-infected cells compared to the control group (Fig. 6f-g ). These results indicated that the treatment of goIFN-l triggered the signalling cascades that lead to the transcription of IFN and IFN-stimulated genes to inhibit DPV replication.
DISCUSSION
Type III IFNs are a novel class of cytokines that exhibit IFN-like antiviral activity in response to virus infection in mammals [19] . Notably, previous studies have reported the cross-reactivity of IFNs in closely related species. The species specificity of interferons was first reported by Tyrrell [20] , who demonstrated that calf and chick interferons failed to induce antiviral activity in heterologous cells. Subsequently, heterologous activity between chick and mouse interferons was reported [21] [22] [23] [24] [25] . Other findings have also indicated that certain human interferons are active in both rabbit cells and human fibroblasts [26] . Human interferons also induce more activity in bovine and porcine cells than in human cells [27] . Moreover, cross-reactivity between pigeon and chicken IFN-g was reported by Fringuelli et al. [28] . It is noteworthy that canine IFN-l has been reported to have potent antiviral activity against vesicular stomatitis virus . DEFs and goPBMCs were cultured in six-well plates and treated with anti-goIFNl PAb for 3 h. goIFN-l (pcDNA3.1 (+)-goIFN-l-transfected BHK-21 supernatants) was subsequently added for another 9 h (blue column). DEF cells and goPBMCs were pre-treated with 100 µl of PBS for 3 h, after which goIFN-l was added for another 9 h (yellow column). As the experimental control, cells were treated with 100 µl of pcDNA3.1 (+)-transfected BHK-21 supernatants under the same conditions as above (red column). The expression of Mx, OASL, IFN-a, IFN-g and IFN-l mRNA was detected by qPCR. Four experimental replicates were performed, and all of the results are shown as mean±SEM. Significant differences from the control groups are indicated by *(P<0.05), ** (P<0.01) and ***(P<0.001).
(VSV), canine parvovirus and influenza virus (H1N1) in both homologous and heterologous animal cells [29] . Despite these findings, cross-antiviral reactivity of goose IFN-a and IFN-g against DPV in duck was reported by our previous study [30] , however, it is unclear whether goIFN-l also exhibits cross-species antiviral activity in duck, even with the high degree of amino acid and nucleotide identity observed. Therefore, to explore the antiviral activity of goIFN-l in DEFs, we first cloned goose type III interferon (unpublished data) and then studied the effects of goIFN-l on heterologous and homologous cells. In the present work, the overexpression and neutralization of goIFN-l in BHK-21 cells was used to explore the antiviral activity of goIFN-l against DPV infection in DEF cells.
Recent studies have shown that duIFN-l increased the level of Mx-1 and OASL transcripts in PDHs [13] . Our results consistently suggested that pre-treatment with goIFN-l causes the potent induction of goMx, goOASL and goIFN expression in goose PBMCs. However, the expression of both duMx and duOASL exhibited little change in goIFN-l pre-treated DEFs. Intriguingly, consistent with the results of the goPBMC model, duIFN-l was clearly up-regulated by goIFN-l in DEFs. This result suggested that a positive self-regulatory feedback loop of goIFN-l exists, and that goIFN-l is capable of binding to receptors for duIFN-l, resulting in the induction of duIFN-l. This finding is reasonable and in agreement with the results of our previous study [17] . The amino acid sequence similarity between goIFN-lR1 and duIFN-lR1 is 90 % [17] , and the reported receptor binding sites for huIFN-l [18] were partially conserved (R 55 , L 56 , Q 100 and F 158 ) between goIFN-l and duIFN-l (Fig. S2) . Moreover, our previous study indicated that goIFN-lR1 is highly expressed in epithelial cell-rich organs (small intestine) and immune tissues [17] , which may partly explain the different reactions of DEFs and Recently, accumulating evidence has advanced our understanding of IFN-l antiviral activity. The antiviral activity of IFN-l was first reported by Ank, who demonstrated that huIFN-l exhibited the strongest inhibitory effect on encephalomyocarditis virus (EMCV) in vitro and herpes simplex virus type 2 (HSV-2) in vivo [31, 32] . The huIFN-l expression is up-regulated after human cytomegalovirus (CMV) infection in mice, and the replication of this virus is markedly reduced by huIFN-l [33] . IFN-l also blocks the replication of HBV and HCV [34, 35] . Additionally, IFN-l has been reported to inhibit some flavivirus infections, such as West Nile virus (WNV) [36, 37] and Dengue virus (DENV) [38] . Murine IFN-l might play a critical role in antiviral defence against murine gammaherpesvirus replication [39] , and bovine IFN-l has potent antiviral activity against foot-and-mouth disease virus (FMDV) in cattle [40] . However, no antiviral IFN-l activity has been reported in waterfowl. Therefore, to evaluate the antiviral activity of goIFN-l on heterologous cells, the BAC-DPV-EGFP virus was chosen. Fluorescence microscopy and FCM showed that the number of GFP-positive cells (infected with DPV) decreased with increasing goIFN-l doses. At 60 h p.i., the replication of BAC-DPV-EGFP was effectively inhibited by the high concentration of goIFN-l (100 µl/well). Notably, the DEFs pre-treated with goIFN-l (100 µl/well) showed a significant decrease in viral copies and titres at both 48 and 60 h p.i. (P<0.001). It is clear that goIFN-l shows crossreactivity antiviral effects in duck cells.
Additionally, the viral copies and titres in the neutralization of the endogenous IFN-l group were significantly increased compared with the control group. These observations indicated that the basal expression of IFN-l contributed to DEF defence against BAC-DPV-EGFP. Therefore, the neutralization of endogenous IFN-l by the anti-goIFN-l PAb increased the sensitivity of cells to the virus, and the suppression of DPV by goIFN-l can be rescued by antigoIFN-l PAb incubation. Further, the endogenous IFN-l is required to inhibit viral infections. Our findings also revealed that pre-treated DEFs with goIFN-l strongly induced the luciferase activity of both pGL3-IFNb-Luc and pGL4-IRSE-Luc. There is ample evidence suggesting that the antiviral activity is collectively mediated by a panel of ISGs that disrupt multiple steps of virus life cycles [4, 41, 42] , such as Mx, OAS and PKR, which have been discovered to be effective antiviral factors. Therefore, as mentioned above, our data revealed that goIFN-l activates signalling cascades that lead to the transcription of IFN and IFNstimulated genes, and ultimately release the IFN and ISG proteins to inhibit DPV replication in DEFs, although further study will be required to obtain direct evidence for the antiviral effects of goose ISGs.
Taken together, our findings confirmed the cross-species antiviral function of goIFN-l in heterologous cells (DEFs).
Treating DEFs with high concentrations of goIFN-l provided effective protection for cells against BAC-DPV-EGFP infection. However, low concentrations of goIFN-l had very mild inhibitory effects on DPV, possibly due to low IFN expression and no obvious change in Mx and OASL expression. Therefore, we hypothesized that the antiviral activity of goIFN-l against DPV in DEFs depended on the concentration of goIFN-l and the subsequently induced ISGs (probably not Mx and OASL).
Similarly, our results are consistent with a previous study on chIFN-l. chIFN-l shows mild antiviral activity in response to influenza virus (PR8) in DF-1 cells, while higher doses of chIFN-l exhibit a stronger antiviral effect [14] . However, additional evidence suggests that chIFN-l can protect CEFs from SFV infection and reduce the replication of PR8 in DD11 cells [12] . These findings demonstrated that ISG expression levels were vastly different during virus infection or IFN treatment, which might be dependent on time, dose and cell type. In general, IFN-l predominantly acts on epithelial cells [43] . Therefore, a rational hypothesis is that there is a certain linear correlation between binding affinity (the interaction between IFN and its cognate receptor) and antiviral activity, with the binding affinity determining the potency of IFN's antiviral activity [44] . It is also probable that fibroblasts exhibit low IFN-l activity, resulting in mild antiviral activity (when DEFs were stimulated with a low concentration of goIFN-l). It is possible that further increasing the dosage or changing the cell type will result in a more pronounced antiviral effect.
In conclusion, we evaluated the antiviral activity of goIFN-l in vitro, and our results indicated that goIFN-l showed cross-species antiviral activity that inhibited the replication of BAC-DPV-EGFP in heterologous DEF cells. Further, the suppression of DPV by goIFN-l can be rescued by antigoIFN-l PAb incubation. By detecting the luciferase activity of both pGL3-IFNb-Luc and pGL4-IRSE-Luc (by reporter gene assays), the antiviral effects of goIFN-l in DEFs were related to the positive self-regulatory feedback loop. Our study may shed further light on goose IFN cross-species antiviral responses and could provide valuable insights for clinical studies. Moreover, more work is required in this area to further address the antiviral mechanism of goIFN-l. Notably, additional investigations are required to determine ) Analysis of luciferase activities, which were determined with a Dual-Glo Luciferase assay system (Promega) and normalized on the basis of the Renilla luciferase activities. All luciferase reporter assays were repeated three times.
the different viruses and cell types that might be affected by goIFN-l.
METHODS

Ethics statement
The animal studies were approved by the Institutional Animal Care and Use Committee of Sichuan Agricultural University (no. XF2014-18) and followed the National Institutes of Health guidelines for the performance of animal experiments.
Cell cultures and viruses BAC-DPV-EGFP virus was constructed by our research centre and then employed in this study. Furthermore, the viral titre of BAC-DPV-EGFP was determined by tissue culture infective dose (TCID 50 was 10
À6.125 /0.1 ml) in DEFs. BHK-21 cells, DEFs and GEFs were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco Life Technologies, Shanghai, China) supplemented with 10 % fetal bovine serum (FBS) at 37 C, 5 % CO 2 and a cell density of approximately 1.0Â10 7 cells/well. The goPBMCs were prepared as previously described [45] .
Prokaryotic expression and purification of recombinant goIFN-l in E. coli BL21 Primers (forward: 5¢-CATGCCATGGCCTTCCCCCAG-GACGCCCCG-3¢; reverse: 5¢-GAACCCAAGCTTGCAGC CGTCTCTCAGCCT-3¢) were designed to amplify the goIFN-l (GenBank accession number: KX377964) open reading frame (ORF) without the signal peptide sequence. The amplified DNA fragment was cloned into the pET32a (+) (Novagen, Madison, WI) expression plasmid to generate pET32a (+)-goIFN-l. The recombinant expression plasmid pET32a (+)-goIFN-l was sequenced to confirm the construct and was transformed into the E. coli BL21 strain.
The goIFN-l expression was induced with the addition of isopropylthio-D-galactoside (IPTG) at a final concentration of 0.8 mM for 4 h at 37 C. The bacteria were harvested by centrifugation (8000 g for 10 min) and broken by ultrasonication on ice before the his-tagged recombinant plasmid containing the goIFN-l fusion protein was purified with Ni-NTA His-Bind resin (EMD Millipore Corp., Billerica, MA, USA) according to the manufacturer's protocol. The purified protein was dialysed with urea to obtain different concentrations and verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot.
Generation of a polyclonal antibody against goIFN-l To generate a polyclonal antibody against the goIFN-l protein, six Kunming mice were immunized with 50 µg purified goIFN-l-his fusion protein mixed with an equal volume of Freund's complete adjuvant (1 : 1, v/v) on day one. The second and third immunizations with incomplete Freund's adjuvant were performed at 2-week intervals. All of the antisera collected were purified with a protein A antibody purification kit (Genscript, Nanjing, China) according to the manufacturer's protocol. A Western blot assay was then performed to confirm the presence of purified mouse antigoIFN-l PAb.
Eukaryotic expression of goIFN-l in BHK-21 cells Primers (forward: 5¢-CTAGCGTTTAAACTTAAGCTTGC CACCATGTTCCCCCAGGACGCCCCG-3¢; reverse: 5¢-TGCTGGATATCTGCAGAATTCTCAGTGGTGGTGGT GGTGGTGGC AGCCGTCTCTCAGCCT-3¢) were generated by PCR, and the product was cloned into the pcDNA3.1 (+) vector using the ClonExpress II One-Step Cloning Kit (Vazyme, Nanjing, China) according to the manufacturer's instructions. Then, the recombinant plasmid pcDNA3.1 (+)-goIFN-l or the pcDNA3.1 (+) vector was transfected into BHK-21 cells. Cell lysates and culture supernatants from BHK-21 cells were harvested at 24, 48 and 72 h post-transfection, clarified by centrifugation at 500 g for 10 min after freezing/thawing three times and stored at À80 C until use.
The his-tagged goIFN-l protein was verified by SDS-PAGE and Western blot using a diluted ( 
The cell cytotoxicity of goIFN-l in DEFs
To evaluate the cytotoxicity of goIFN-l in DEFs, a CellCounting Kit-8 (CCK-8) assay (Beyotime Biotech, Nanjing, China) was performed according to the manufacturer's instructions. In brief, 100 µl of DEFs (2Â10 5 cells/well) were seeded in 96-well plates and incubated at 37 C with 5 % CO 2 . Twenty-four hours later, the cells were treated with 10 µl of the culture supernatants from pcDNA3.1 (+)-goIFN-l-transfected BHK-21 cells for 3, 6, 12 and 24 h. Similarly, the control group was treated with 10 µl of the culture supernatant from pcDNA3.1 (+)-transfected BHK-21 cells. In addition, phosphate-buffered saline (PBS)-treated cells served as a negative control. The blank control contained 100 µl of medium alone (no cells). Subsequently, 10 µl of CCK-8 reagent was added into each well for a 2 h incubation at 37 C. The plates were then evaluated by a multi-detection microplate reader using the 450 nm wavelength. The results were expressed relative to control cells, which were defined as having 100 % viability.
Immunoregulation study of goIFN-l in vitro DEFs were grown overnight in six-well plates. Subsequently, the cells were washed with pre-warmed PBS and treated with 100 µl of goIFN-l for 6, 12 or 24 h in DMEM containing 2 % FBS. After treatment, the culture supernatant was removed, and cells were harvested with 1 ml RNAiso Plus reagent (Takara Bio, Otsu, Japan) for RNA extraction. Cells treated with 100 µl of pcDNA3.1 (+) served as the control group. GEFs were grown under the same conditions as described above. The goPBMCs (5Â10 5 cells ml À1 ) were grown in six-well plates with Gibco RPMI 1640 (Gibco Life Technologies, Shanghai, China) containing 10 % FBS. Six hours later, the cells were treated with 100 µl of goIFN-l for 6, 12 or 24 h. The cells in the control group were treated with 100 µl of pcDNA3.1 (+)-transfected BHK-21 supernatants and grown under the same conditions as described above. Thereafter, cells were collected by centrifugation at 500 g for 5 min and immediately resuspended in 1 ml RNAiso Plus reagent for RNA extraction. The expression of three types of IFN (IFNa, IFNg, IFNl) and ISG (Mx and OASL) in the treated cells was detected by quantitative realtime PCR (qPCR).
The positive self-regulatory feedback loop of goIFN-l in DEF cells was reduced by anti-goIFN-l PAb DEFs were grown overnight in six-well plates. The cells were washed with pre-warmed PBS and immediately treated with 100 µl of PBS or goIFN-l for 3 h in DMEM containing 2 % FBS. Subsequently, the cells in each well were incubated with 100 µl of anti-goIFN-l PAb for another 9 h. The control cells were treated with 100 µl of pcDNA3.1 (+)-transfected supernatants under the same conditions as described above. After treatment, the culture supernatant was removed, and the cells were harvested with 1 ml RNAiso Plus reagent for RNA extraction.
Isolation of RNA and analysis of cytokine mRNA expression by qPCR Total RNA was isolated from selected tissues using the RNAiso Plus reagent. The quantity of RNA in each sample was determined using a NanoDrop 2000 (Thermo, Waltham, MA, USA), and RT-PCR was performed on each sample using a 5Â all-in-one RT Master Mix reagent kit in accordance with the manufacturer's instructions (Applied Biological Materials, Richmond, BC, Canada). Finally, the cDNAs were stored at -80 C until use. The qPCR was used to detect the expression of IFN (IFN-a, IFN-g and IFN-l) and ISG (Mx and OASL) mRNAs in DEFs, GEFs and goPBMCs. The primer sequences used are listed in Table 1 .
The qPCR was performed using the Bio-Rad CFX96 Real Time Detection System (Bio-Rad, USA). Threshold cycle (Ct) values were normalized to the housekeeping genes dub-actin or goGAPDH, and the relative expression levels of each target gene were calculated with the comparative Ct (2
ÀDDCt
) method. The real-time PCR conditions and protocols were described previously [46] . Subsequently, a standard curve was built using serially diluted BAC-DPV-UL30-EGFP plasmid standards at 10 4 -10 8 copies/µl. Therefore, BAC-DPV-EGFP DNA was extracted from the samples (200 µl) above using a nucleic acid extraction kit (Tiangen, Shanghai). Then, BAC-DPV-EGFP copies were detected by qPCR using special primers based on the DPV-UL30 gene (shown in Table 1 ).
Antiviral effect of goIFN-l against DPV in DEFs
Finally, the BAC-DPV-EGFP titres were determined by an endpoint dilution assay in the DEFs. The titres were expressed as TCID 50 per millilitre, and the results were analysed using the Reed-Muench method [47] . Briefly, 100 µl of the supernatant from pcDNA3.1 (+)-goIFN-l-transfected cells or mouse anti-goIFN-l PAb for 12 h and infected with BAC-DPV-EGFP for 48, 60 h, were multiple 10-fold diluted (100 µl) and seeded in eight replicates in 96-well plates. After absorption for 1 h at 37 C, the supernatants were removed, and the cells were incubated with DMEM containing 1 % FBS. The plates were incubated for 72-120 h, and the viral titres were Antiviral mechanism of goIFN-l by reporter gene assays DEFs were cultured overnight in 12-well plates at 37 C before transfection. A sequence of the duck IFNb promotor region (GenBank accession number: KM032183.1) was inserted into the pGL3 luciferase reporter vectors to form pGL3-IFNb-Luc. The commercial pGL4-IRSE-Luc plasmid was purchased (Promega, Madison, WI, USA). First, the pGL3-IFNb-Luc (1600 ng/well) or pGL4-IRSE-Luc (1600 ng/well) plasmid was transiently transfected into prepared DEFs (divided into four groups), respectively. Four groups were transfected with pRL-TK plasmid (160 ng/ well) (Promega, Madison, WI, USA), which acted as an internal control to normalize transfection efficiency. The detailed workflow is shown in Fig. 6 (a), and is briefly described as follows. Group 1 (control group) was only treated with 100 µl supernatant from pcDNA3.1 (+)-transfected cells. Group 2 was only treated with 100 µl of goIFNl. Group 3 was treated with 100 µL of goIFN-l for 3 h, and then 100 µl of mouse anti-goIFN-l PAb was added. Group 4 was only treated with 100 µl of mouse anti-goIFN-l PAb. After treatment, all groups were infected with BAC-DPV-EGFP (containing 100 TCID 50 , 200 µl/well). At 48 h p.i., the cells were harvested for luciferase assays, FCM analysis, virus copies and titre detection. The luciferase activities were determined with a Dual-Glo Luciferase assay system (Promega) and normalized on the basis of the Renilla luciferase activity.
Calculations and statistics
The statistical analyses were performed on single and paired samples and were performed with GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA). The differences between the values were evaluated by Student's t-test. P<0.05 was considered to be statistically significant, and all values are expressed as mean±SEM.
